Bristol-Myers Squibb
Bristol-Myers Squibb Company, commonly referred to as BMS, is a leading global biopharmaceutical firm headquartered in the United States. Founded in 1887, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative medicines in oncology, immunology, and cardiovascular disease. BMS is renowned for its groundbreaking therapies, such as Opdivo and Eliquis, which have transformed treatment paradigms and improved patient outcomes. The company’s commitment to research and development has positioned it as a key player in the pharmaceutical industry, consistently achieving significant milestones, including numerous FDA approvals and recognitions for its contributions to healthcare. With a robust pipeline and a dedication to addressing unmet medical needs, Bristol-Myers Squibb continues to solidify its market position as a pioneer in biopharmaceutical innovation.
DitchCarbon Score
How does Bristol-Myers Squibb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bristol-Myers Squibb's score of 74 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bristol-Myers Squibb's reported carbon emissions
In 2023, Bristol-Myers Squibb (BMS) reported total greenhouse gas emissions of approximately 2,117,929,000 kg CO2e. This includes 208,535,000 kg CO2e from Scope 1 (direct emissions), 158,447,000 kg CO2e from Scope 2 (indirect emissions), and a significant 1,750,947,000 kg CO2e from Scope 3 (value chain emissions). BMS has set ambitious climate commitments, aiming for net-zero emissions across all scopes by 2050. In the near term, the company targets a 54.6% reduction in absolute Scope 1 and 2 emissions by 2033, using 2022 as the baseline year. Additionally, BMS plans to reduce Scope 3 emissions from fuel and energy-related activities by the same percentage within the same timeframe. The company also commits to ensuring that 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. Furthermore, BMS aims to achieve net neutrality in Scope 1 and 2 emissions by 2040, alongside a long-term goal of reducing absolute Scope 1 and 2 emissions by 90% by 2050. These initiatives reflect BMS's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol-Myers Squibb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
